88 related articles for article (PubMed ID: 1495748)
1. Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
Brivio F; Lissoni P; Tisi E; Erba L; Barni S; Tancini G; Rescaldani R; Alderi G; Nociti V
Oncology; 1992; 49(3):215-8. PubMed ID: 1495748
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of surgery-induced decline in circulating dendritic cells by subcutaneous preoperative administration of IL-2 in operable cancer patients.
Brivio F; Lissoni P; Gilardi R; Ferrante R; Vigore L; Curzi L; Uggeri F; Nespoli A; Fumagalli L
J Biol Regul Homeost Agents; 2000; 14(3):200-3. PubMed ID: 11037053
[TBL] [Abstract][Full Text] [Related]
3. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
4. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
5. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Oncology; 1996; 53(4):263-8. PubMed ID: 8692528
[TBL] [Abstract][Full Text] [Related]
6. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
Masotti A; Morandini G; Ortolani R; Fumagalli L
Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
[TBL] [Abstract][Full Text] [Related]
7. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
Eur J Surg; 1993 Jan; 159(1):43-7. PubMed ID: 8095806
[TBL] [Abstract][Full Text] [Related]
8. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
10. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
11. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications.
Brivio F; Lissoni P; Perego MS; Lissoni A; Fumagalli L
J Biol Regul Homeost Agents; 2001; 15(4):370-4. PubMed ID: 11860226
[TBL] [Abstract][Full Text] [Related]
13. Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline.
Brivio F; Lissoni P; Rovelli F; Nespoli A; Uggeri F; Fumagalli L; Gardani G
Hepatogastroenterology; 2002; 49(44):385-7. PubMed ID: 11995457
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.
Deehan DJ; Heys SD; Simpson W; Broom J; McMillan DN; Eremin O
Br J Surg; 1995 Jan; 82(1):86-90. PubMed ID: 7881967
[TBL] [Abstract][Full Text] [Related]
15. Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopenia.
Brivio F; Lissoni P; Fumagalli L; Brivio O; Lavorato F; Rescaldani R; Conti A; Roselli M; Maestroni G; Barni S
Oncol Rep; 1995 Jul; 2(4):597-9. PubMed ID: 21597783
[TBL] [Abstract][Full Text] [Related]
16. [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
Arch Ital Urol Androl; 1997 Feb; 69(1):49-54. PubMed ID: 9181906
[TBL] [Abstract][Full Text] [Related]
17. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.
Nichols PH; Ramsden CW; Ward U; Sedman PC; Primrose JN
Cancer Res; 1992 Oct; 52(20):5765-9. PubMed ID: 1394200
[TBL] [Abstract][Full Text] [Related]
18. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
[TBL] [Abstract][Full Text] [Related]
19. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]